Market Overview

UPDATE: Morgan Stanley Reiterates On St. Jude Medical On Mixed Factors

Share:
Related STJ
Argus Says Abbott Laboratories Shares Favorably Valued Despite 'Heightened' M&A Risks
Focus On Abbott Labs Remains On Pending Deals

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on St. Jude Medical (NYSE: STJ), but removed the $75.00 price target.

In the report, Morgan Stanley noted, “We remain comfortable that St. Jude's top line is poised for acceleration given underlying business strength, CRT-D momentum and CardioMEMs. However, Nanostim's early European failures and MDT's more positive comparative experience did raise concerns at HRS.”

St. Jude Medical closed on Thursday at $63.22.

Latest Ratings for STJ

DateFirmActionFromTo
Jul 2016WedbushDowngradesOutperformNeutral
Jul 2016Leerink SwannDowngradesOutperformMarket Perform
May 2016BarclaysDowngradesOverweightEqual-weight

View More Analyst Ratings for STJ
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (STJ)

View Comments and Join the Discussion!